A series of cardiometabolic-related news items have been observed from Lilly, Xeris Biopharma, Lexicon Pharmaceuticals, and Inventiva. Below, FENIX provides highlights and insights for the respective news items.
On the third day of ADA 2024, four cardiometabolic-related news items have been observed from Senseonics, Altimmune, Fractyl Health, and Gan & Lee. Below, FENIX provides context and analysis for the announcements.
On the second day of ADA 2024, six cardiometabolic-related news items have been observed from Insulet, Medtronic, Terns Pharmaceuticals, MannKind, Tandem, and Altimmune. Below, FENIX provides context and analysis for the announcements.
To kick off the ADA 2024 conference, FENIX sat down with Leif Bowman, the co-founder of Allez Health, for an in-depth interview on the company’s goal to disrupt the CGM market. Recall, in May 2024, Allez announced it secured $60M in a Series A+ financing round led by Osang Healthcare Co. Ltd and with participation from existing investors (previous FENIX insight). For context, Allez (formerly called Zense-Life; view website) is an emerging biosensor venture founded by veterans in the CGM space. Below, FENIX provides Part 1 of our exclusive interview which includes insight into Allez’s business philosophy as well as an early look into the features of its CGM.
A series of cardiometabolic-related news items have been observed from Insulet/Dexcom, Zealand, Ypsomed, Silence Therapeutics, and Lilly. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Pfizer, Vivani Medical, Novo Nordisk/Biosplice Therapeutics, and Sagimet Biosciences. Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news have been observed: Abbott announced FDA cleared its Lingo and new “Libre Rio” CGM systems for OTC (view press release); Lilly announced detailed results from the Ph2 SYNERGY-NASH trial were presented at EASL 2024 (June 5-8; Milan, IT) and published in the NEJM (view press release); and Teladoc appointed Charles Divita, III, as its CEO effective immediately (view press release). Below, FENIX provides highlights and insights for the respective news items, including thoughts on how Lingo and Libre Rio will compete with Dexcom’s Stelo.
A series of cardiometabolic-related news items have been observed from Novo Nordisk/Metaphore Biotechnologies, Altimmune, Xeris, MannKind, and Viatris. Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Amgen (press release; slides), Regeneron (press release; slides), and Alnylam (press release; slides) hosted their respective Q1 ’24 earnings calls. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Nanexa, SAB, Novartis, Ypsomed, and J&J. Below, FENIX provides highlights and insights for the respective news items.